Trending Now
Unusual call activity (GIS, DBX, DDOG, X)
The stock market has opened up today on a positive note. Wall Street is currently eyeing SPY January 6 $324 Calls. If...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Outlook Therapeutics Inc (NASDAQ:OTLK) Completes The Evaluation Of ONS-5010/LYTENAVA To Cure...
Outlook Therapeutics Inc (NASDAQ:OTLK) completed the evaluation study of ONS-5010/LYTENAVA with the first final visit of the last patient.
Completes two clinical trials
In the open-label...
MAKE IT MODERN
LATEST REVIEWS
Napo Pharmaceuticals Inc, A Subsidiary Of Jaguar Health Inc (NASDAQ:JAGX), Negotiates...
Napo Pharmaceuticals Inc, a wholly-owned subsidiary of Jaguar Health Inc (NASDAQ:JAGX), is in discussions with insurers for better patient access to its Mytesi, plant...
MAKE IT MODERN
PERFORMANCE TRAINING
Minerva Neurosciences Inc (NASDAQ: NERV) Submits New Drug Application for Roluperidone In Treating Negative...
Minerva Neurosciences Inc (NASDAQ: NERV) has announced the submission of a New Drug Application to the US FDA for roluperidone in treating negative schizophrenia...
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Commences Phase 2A Study Evaluating PH94B in Anxiety Treatment
VistaGen Therapeutics Inc. (NASDAQ: VTGN) has announced the commencement of phase 2A clinical study to assess safety, tolerability, and efficacy of PH94B as a...
Stocks in Focus as short interest rises (TTCF,BYND,ALLO,EDIT,SANA,ARQT,IBRX)
During the first half of March, sophisticated market participants heightened their short positions against plant-based food producer Tattooed Chef (NASDAQ:TTCF) and numerous...
Savara Inc. (SVRA): Progress in Rare Respiratory Disease Treatment with MOLBREEVI
Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, saw its stock close at $3.15 on December 27,...
Churchill Capital IV (NYSE:CCIV) could be the next Tesla (NASDAQ:TSLA)
Churchill Capital IV (NYSE:CCIV) hit a new high today, as investors continue to believe it will soon announce a merger with luxury electric-vehicle (EV)...
MAKE IT MODERN
